Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Understanding when to shift from stocks to bonds can enhance your investment strategy. Make informed decisions to maximize returns.
22,202 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Two market leaders just lit up a golden cross, drawing investor attention to Best Buy and Visa. Here’s a concise read...
Toast is showing renewed momentum as its growth engine—international expansion, a growing enterprise pipeline, and a ...
A drone leader sparked fresh optimism as AeroVironment stock took flight this week, jumping on news of real-world cou...
A new AI-powered marketing platform is offering shares at $0.85 in a Reg A+ round, drawing comparisons to early Nvidi...
As mdxhealth (MDXH) 2025 earnings unfold, investors watch cash burn, pipeline progress, and strategic partnerships. T...
A surprise take-private bid sent AES stock tumbling and left investors wondering what comes next. This guide breaks d...
A major fund just disclosed a sizable stake in Tango Therapeutics (TNGX), totaling about $9.5 million. This move shin...
When a defense stock pops, investors want the quick answer: is this a one-off move or a real trend? This article brea...
SanDisk shares jumped on fresh momentum as data-center demand and NAND constraints propel a potential multi-year rall...
SCHD will conduct its annual reconstitution on March 23, trimming energy exposure and leaning more on financials to d...
A leading AI stock is rumored to have secured a deal worth over $100 billion. This article breaks down what that coul...